Visit the Repositive booth (#4628) to see just how many preclinical cancer models we can connect you with via our Cancer Models Scout service
Share your experience of modelling tumour metastasis in our informal roundtable discussion.
The Repositive Team is excited to be heading back to the American Association of Cancer Research (AACR) annual conference in Atlanta this April. In just a year, we’ve built up the world’s largest inventory of preclinical cancer models – over 4,500 from 14 CROs and specialist providers across the globe. We’ve got everything from PDX and CDX models, organoids and cell lines, to syngeneic and humanised mice. And, via our confidential Cancer Models Scout service we’ve slashed search times for researchers looking for models from months down to just a few weeks.
Come along to the Repositive booth (#4628) at AACR 2019 to explore our new, interactive Cancer Models App and see for yourself just how many models we can connect you with.
If you’d like to arrange a 1-2-1 meeting with one of our cancer model experts ahead of the show, please email: firstname.lastname@example.org
Here is where you can find the Repositive Team at AACR 2019 (booth number #4628)
Don't miss our roundtable discussion on modelling metastasis in preclinical drug development
Cancer doesn’t kill most patients, metastasis and recurrence do.
That’s why biopharma must develop effective therapies for not just primary tumours but also for metastatic growths and secondary tumours that have developed resistance to first-line therapy.
But developing the new generation of precision cancer therapies is difficult when the vast majority of animal models available for preclinical research are based on evaluating primary tumour sites and the literature for modelling metastases in vitro is still relatively small!
As part of our ongoing programme of events looking at hot topics in translational oncology on Tuesday 2 April, 2019 (18:30-21:30 EDT) we’re hosting an informal roundtable discussion on the challenges with modelling metastasis and recurrence.
Come along to share your experiences, exchange top tips with industry peers and have your say on what the next generation of preclinical cancer research will look like.
See you there!